Measuring real-time PK/PD by monitoring aberrant chaperone activity

Measuring PK/PD in real time by selectively targeting protein networks

A Memorial Sloan Kettering Cancer Center team developed an imaging probe for aberrant protein networks that could guide more optimal drug dosing and scheduling earlier in development.

In cancer, tumor biopsy collection as well as heterogeneity within tumors and among patients present logistical

Read the full 426 word article

User Sign In